Documenting medication informed consent in psychiatry: what the note has to show

By Selam Koch, PMHNP-BC, founder of OneStep Scribe and practicing psychiatric nurse practitioner. Published August 2026.

Informed consent for psychiatric medication is a conversation, and the note is often the most durable and persuasive evidence that the conversation happened. A signature on a form proves a signature was obtained. It does not prove the patient heard about tardive dyskinesia before starting an antipsychotic, or asked whether the weight gain is reversible, or weighed the option of trying therapy first. Years later, if a board investigator or a plaintiff's attorney asks what the patient was told, the form alone says little about what was actually discussed, while a specific note entry can say a great deal. This guide covers what a consent entry should contain, how to handle the serious class-specific risks, capacity, minors, ongoing consent, and what a well-documented entry looks like in practice.

Consent is a process, and the note is its record

The prevailing legal and ethical understanding treats informed consent as a process of shared decision making rather than a document, though the legal weight given to a signed form varies by state, and in some states a properly executed form carries a statutory presumption of valid consent. The prescriber discloses the material information, the patient processes it, asks questions, and makes a choice, and the choice is honored. The form, where one is used, is a supplement. Some states and some settings require written consent for specific treatments, and antipsychotics in particular carry statutory consent requirements in several jurisdictions, so verify the rules where you practice. But in ordinary outpatient prescribing, the note entry describing the conversation is the core of the record.

Structurally, consent documentation should have a consistent home in your note. Many structured psychiatric templates carry a dedicated, clearly labeled informed consent section after the plan, separate from the medication list and the medical necessity language, so that a reviewer can find it without hunting. Where it lives matters less than that it lives somewhere predictable and gets written at the right moments.

The six elements a consent entry should reflect

A complete consent entry does not need to be long. It needs to show that the essential content of the conversation was covered. Six elements do that work:

1. Diagnosis and indication. What condition is being treated and why medication is on the table. One clause is enough when the diagnostic formulation lives elsewhere in the note.
2. Material risks discussed. The serious class-specific risks and the common side effects a reasonable patient would want to know before deciding (the widely used materiality standard; some states instead measure disclosure against professional custom). Named, not gestured at.
3. Expected benefits. What improvement is realistically anticipated and roughly on what timeline, stated without promising a result.
4. Reasonable alternatives, including no medication. Other medication classes, psychotherapy, combined treatment, and the option of declining medication along with the likely course of untreated illness. The alternative of doing nothing is one frequently missing from notes, and it is the one that shows the choice was real.
5. Patient questions answered. What the patient asked and, briefly, what you said. A documented question is powerful evidence of a genuine two-way exchange, because boilerplate does not ask questions.
6. The patient's decision. Agreed to start, wanted time to think, declined, or chose an alternative. A declination documented respectfully, showing the patient had capacity, that the risks of declining were reviewed, and what follow-up was offered, is itself sound consent documentation.

Documenting the serious class-specific risks

The disclosures that matter most legally are the serious, class-level risks, and the note should show they were discussed in terms the patient could use. None of this requires dosing detail or product promotion in the note. General class language is exactly right.

Antipsychotics: tardive dyskinesia and metabolic effects

For any dopamine-blocking antipsychotic, the consent entry should show that the risk of tardive dyskinesia was discussed, including the possibility that it can persist after the medication stops. This is one of the psychiatric consent issues with the longest litigation history, and it is also where ongoing documentation earns its keep: periodic structured screening for abnormal involuntary movements, such as an AIMS assessment documented at regular intervals, creates a contemporaneous record that you were watching for the harm you disclosed. Metabolic effects belong in the same conversation. Document that weight gain, glucose, and lipid effects were discussed and that baseline and periodic metabolic monitoring is planned.

Antidepressants: the boxed warning in young patients

When starting an antidepressant in a child, adolescent, or young adult, document that the boxed warning about increased suicidal thoughts and behaviors in patients under 25 was discussed, that the patient, and family where involved, were told what changes to watch for, and that early follow-up was arranged. The warning discussion and the monitoring plan belong together, because the disclosure without the safety netting is half an answer.

Lithium: toxicity and the monitoring bargain

Lithium consent is fundamentally a monitoring agreement. Document that the patient was told about the narrow margin between a therapeutic level and toxicity, the warning signs of toxicity, the situations that raise levels such as dehydration and certain drug interactions, and the need for periodic blood levels along with renal and thyroid monitoring. The note should show the patient understood that staying on lithium means staying in a lab schedule.

Clozapine: consent to a structured program

Clozapine consent includes the risk of severe neutropenia and the reality that treatment is tied to regular blood count monitoring. The formal program requirements have changed over time, so document the monitoring expectation as it currently applies in your setting, and document that the patient understood continued treatment depends on ongoing blood work. Where a formal monitoring program applies, note the enrollment conversation.

Capacity: document the four abilities, not just a conclusion

Consent is only valid if the patient had the capacity to give it, and "patient has capacity" is a conclusion, not evidence. The widely used framework asks four functional questions, and a strong note speaks to them: the patient could understand the relevant information, appreciate how it applies to their own situation, reason about the options, and express a choice that holds steady. In routine practice one sentence covers it, for example that the patient restated the risks in their own words and weighed the alternatives before deciding.

When capacity is genuinely in question, the documentation burden rises. Record what you observed against each of the four abilities, what the deficit was, and what you did about it: involving a guardian or conservator, obtaining consent from the legally authorized decision maker, verifying that person's authority, and recording the patient's own assent or objection alongside the substitute consent. Capacity is decision-specific, so a patient may validly consent to a medication refill while lacking capacity for a more complex decision, and it can fluctuate, so reassess when the clinical picture changes. The mechanics of substitute consent, including who qualifies and what paperwork applies, vary by state.

Consent is ongoing, not a one-time event

The initial consent conversation covers the decision made that day. It does not cover the treatment relationship forever. Re-document consent when something material changes:

• A new agent starts. Every new medication is a new consent conversation, even within the same class.
• A dose changes materially. A change large enough to shift the risk picture, or to cross a threshold where new monitoring applies, warrants a documented conversation.
• New risks emerge. A new pregnancy, an abnormal lab, a new interacting medication, emerging movement symptoms, or new safety information about the drug all reopen the discussion.

Routine continuation deserves a lighter touch. A single sentence confirming that the patient discussed the current regimen and chose to continue it keeps the thread of ongoing consent visible across the chart without turning every follow-up into a re-consent ceremony.

Minors: assent plus guardian consent

Prescribing for a minor involves two documented conversations. The guardian provides legal consent, and the note should identify who consented and their relationship to the child, and show the same elements as adult consent: indication, material risks, benefits, alternatives, questions, decision. The minor provides assent, and the note should show the child received an age-appropriate explanation, had the chance to ask questions, and expressed willingness, reluctance, or refusal in their own terms. A documented assent conversation also matters clinically, because an adolescent who never agreed to a medication is unlikely to take it. State law complicates this area considerably: age of consent for mental health treatment, the rights of minors to consent to their own care in some circumstances, and the rules for divorced or separated parents all vary by jurisdiction, so know the rules where you practice and document which adult held the authority.

How thin consent documentation surfaces later

Three settings routinely test consent documentation, and it is worth knowing what each one looks for, without dramatizing any of them.

Board complaints. Licensing boards investigating a prescribing complaint request the chart, often years after the visits in question. At that distance, nobody's memory of a specific conversation is evidence. The note is. An entry naming the risks discussed and the patient's questions gives the board something concrete; a bare boilerplate line gives it nothing to weigh.

Malpractice discovery. In a medication injury claim, failure to obtain informed consent is frequently pleaded alongside negligence. The chart is produced, and the consent entries are compared against testimony. Contemporaneous documentation of a specific conversation is among the strongest support the defense can offer that disclosure happened, though no documentation guarantees an outcome. Identical consent language repeated across every visit and every patient reads as template output and is treated accordingly.

Payer review. Payer chart reviews are primarily about medical necessity and code support rather than consent as such, but risk discussion documentation participates: prescription drug management sits in the risk column of medical decision making, and a note that shows an actual risk and benefit conversation supports the management work the visit claims. Payer expectations vary by plan, so no single documentation pattern satisfies all of them.

A worked example

Here is what a complete consent entry can look like for a medication start, using class language and no dosing. Adjust the specifics to the actual conversation, because the value of the entry is that it happened this way.

Frequently asked questions

Is a signed consent form enough to document medication informed consent?

A signed form documents that a signature was obtained, not that a conversation happened. Forms have value, and some states and settings require them for specific treatments, but reviewers who evaluate consent read the clinical note for evidence of a discussion: what was disclosed, what the patient asked, and what the patient decided. The strongest record is a brief note entry describing the actual conversation, with a form attached where one is used, rather than a form standing alone.

Do I need to re-document informed consent at every visit?

No. Consent documentation is expected at decision points, not at every encounter. Document the initial discussion when a medication starts, then again when something material changes: a new agent, a substantial dose change, a newly relevant risk such as pregnancy or an abnormal lab, or a shift in the risk and benefit picture. At routine follow-ups, a brief line confirming the patient discussed the current regimen and wishes to continue it is reasonable and takes one sentence.

How do I document consent when the patient's capacity is in question?

Document the four functional abilities specifically: whether the patient could understand the relevant information, appreciate how it applies to their own situation, reason about the options, and express a consistent choice. If one or more is impaired, document what you observed, who provided consent instead, such as a guardian or conservator, the basis for that person's authority as you verified it, and the patient's own assent or objection. Capacity is decision-specific and can fluctuate, so revisit it when the clinical picture changes. Procedures for substitute consent vary by state.

How do I document consent for a minor?

Document both halves: the guardian's consent and the minor's assent. Note who the consenting adult was and their legal relationship to the child, that risks, benefits, and alternatives were discussed with them, and that the minor received a developmentally appropriate explanation and had the chance to ask questions. Record the minor's response in their own terms where possible. Age thresholds and minor consent rights vary widely by state, so verify the rules where you practice.

Do I need to list every side effect discussed in the note?

No, and trying to be exhaustive can work against you, because a long list you did not actually cover is less credible than a short one you did. The widely used standard is material risks: the serious ones and the common ones a reasonable patient would want to know before deciding. Name the significant class-specific risks you discussed, note that common side effects were reviewed, and record any risk the patient specifically asked about. The note should reflect the conversation that happened, not the package insert.

What should the note say about a boxed warning discussion?

Name the warning in plain terms and tie it to the plan. For example, a note might state that the boxed warning regarding suicidal thoughts and behaviors in patients under 25 starting antidepressants was discussed, that the patient and family were told what changes to watch for, and that early follow-up was scheduled. That entry shows the disclosure, the safety netting, and the monitoring response without reproducing label language.

Related guides

• Psychiatric progress note example, annotated section by section
• Writing treatment plans with measurable goals
• Billing 99214 with 90833: the rules that make it defensible
• Telehealth psychiatry documentation requirements
• Prior authorization documentation in psychiatry
• Choosing an AI scribe as a psychiatric prescriber

This article is educational and reflects one clinician's understanding of documentation practices at the time of writing. It is not legal or medical advice, and it does not guarantee any licensing, litigation, payer, or clinical outcome. Informed consent requirements vary by state, setting, and payer, and they change; consult a qualified attorney or compliance professional for guidance on your specific obligations, and verify current payer requirements with the plans you bill. Documentation tools support clinical and legal judgment; they do not replace it.